2018.09.20
On September 14th 2018, Hua Medicine completed its IPO in Hong Kong and issued 104,756,000 shares globally, issuing price was HKD 8.28 per share, raising fund of HKD 0.867 billion in total (approximately USD 0.11 million).
Hua Medicine was m88 bonus third Chinese biotechnology firm successfully listed on m88 bonus HKEx since m88 bonus HKEx issued m88 bonus new regulations that encouraged m88 bonus non-profiting biotechnology firms’ IPO in Hong Kong in April 2018. m88 bonus developmental base of Hua Medicine is located in Shanghai and is devoted to new medicine R&D which helps cure diabetes. Hua Medicine has accumulated global top-end talents and technology resources, and successfully developed a global initiative for m88 bonus new diabetes drug Dorzagliatin (HMS5552) which has entered m88 bonus process of registered clinical research. m88 bonus firm has conducted 2 III-term clinical researches in China, separately focusing on newly non-treated II-type diabetics and diabetics with no reaction to Metformin. m88 bonus firm has completed 5 series of financing in recent years, famous investors include ARCH Venture Partners, Venrock, AppTec and Eight Roads Capital (owned by Fidelity Group).
JunHe, as m88 bonus PRC law counsel to co-sponsor, provided high-quality, rigorous and efficient legal services including reviewing and modifying deal documents, explaining and responding to domestic listing related issues of m88 bonus HKEx’s concern, successfully gained approval and remit on listing from m88 bonus HKEx. m88 bonus JunHe team’s solid working attitude and professional services were highly recognized by m88 bonus client and om88 bonusr intermediaries.
m88 bonus leading partners were Mr.M88 Game ,合伙人,专业领域,资本市场,私募股权创业投资and Ms.m88 casino app.
